Results 61 to 70 of about 205,975 (308)

Inhaled Angiopoietin‐Like 4 Antisense Oligonucleotide Therapy for Lung Injury and Fibrosis

open access: yesAdvanced Science, EarlyView.
Inhaled antisense oligonucleotides targeting ANGPTL4 attenuate inflammation, preserve barrier integrity, and reduce fibrosis in both infectious and sterile lung injury models. Integrated transcriptomic analysis reveals a conserved ANGPTL4‐regulated gene network coordinating hypoxic, inflammatory, apoptotic, and stress‐response pathways.
Haiyang Fan   +21 more
wiley   +1 more source

Incidence, Disease Severity, and Follow-Up of Influenza A/A, A/B, and B/B Virus Dual Infections in Children: A Hospital-Based Digital Surveillance Program

open access: yesViruses, 2022
Influenza virus (IV) coinfection, i.e., simultaneous infection with IV and other viruses, is a common occurrence in humans. However, little is known about the incidence and clinical impact of coinfection with two different IV subtypes or lineages (“dual ...
Patrick E. Obermeier   +4 more
doaj   +1 more source

Tailoring Vascular‐Immune Homeostasis via Manganese‐DNA Complex‐Armed Immunogenic Extracellular Vesicles for Pancreatic Cancer Immunotherapy

open access: yesAdvanced Science, EarlyView.
This study demonstrates that Mn2⁺–tumor DNA complexes encapsulated in dendritic cell (DC)– derived immunogenic extracellular vesicles (EVDC@Mn‐DNA) act as a DC‐specific cGAS– STING activator. EVDC@Mn‐DNA treatment enhances intratumoral DC activation, improves tumor vascular function, promotes CD8⁺ T cell activity, and suppresses pancreatic tumor growth,
Xue Jiang   +13 more
wiley   +1 more source

Enhanced isolation of influenza viruses in qualified cells improves the probability of well-matched vaccines

open access: yesnpj Vaccines, 2021
Influenza vaccines are utilised to combat seasonal and pandemic influenza. The key to influenza vaccination currently is the availability of candidate vaccine viruses (CVVs).
Heidi Peck   +9 more
doaj   +1 more source

Attenuation of Influenza a Virus into Live Vaccines Through C‐End Degrons

open access: yesAdvanced Science, EarlyView.
Naturally occurring C‐end degrons are exploited to design proteolysis‐targeting live attenuated influenza vaccines. C‐end degron tagging of viral M1 protein promotes proteasome‐dependent degradation, resulting in robust attenuation in host cells while permitting scalable production in engineered cells.
Ping Wang   +14 more
wiley   +1 more source

Testicular mRNA‐LNP Delivery: A Novel Therapy for Genetic Spermatogenic Disorders

open access: yesAdvanced Science, EarlyView.
In the current study, we developed a novel therapy for genetic spermatogenic disorders. It was revealed that in vivo delivery of mRNA LNP3 could restore spermatogenesis in Msh5D486Y/D486Y and Maps KO mouse models with meiotic arrest. Notably, the offspring without genomic integration was born using ICSI derived from the rescue of Msh5D486Y/D486Y mouse ...
Chenwang Zhang   +22 more
wiley   +1 more source

TIV vaccination modulates host responses to influenza virus infection that correlate with protection against bacterial superinfection [PDF]

open access: yes, 2019
Background: Influenza virus infection predisposes to secondary bacterial pneumonia. Currently licensed influenza vaccines aim at the induction of neutralizing antibodies and are less effective if the induction of neutralizing antibodies is low and/or the
Choi, Angela   +4 more
core   +2 more sources

RNF213 Is an Interferon‐Stimulated Gene That Targets Influenza A Virus NP and Activates MDA5 to Restrict Infection

open access: yesAdvanced Science, EarlyView.
RNF213 is characterized as a dual‐functional antiviral effector. It directly mediates the degradation of the influenza A virus nucleoprotein (NP) while simultaneously activating the MDA5‐mediated innate immune signaling pathway. This coordinated response establishes a powerful host defense system against viral infection. ABSTRACT Influenza A virus (IAV)
Haoning Li   +5 more
wiley   +1 more source

Bacterially produced recombinant influenza vaccines based on virus-like particles. [PDF]

open access: yesPLoS ONE, 2013
Although current influenza vaccines are effective in general, there is an urgent need for the development of new technologies to improve vaccine production timelines, capacities and immunogenicity.
Andrea Jegerlehner   +6 more
doaj   +1 more source

Influenza vaccine efficacy [PDF]

open access: yesCanadian Medical Association Journal, 2015
I am writing in response to a recent news article[1][1] published in CMAJ . The lack of efficacy of this year’s vaccine preparation is often used as an argument against vaccination. Although the match between the vaccine H3N2 strain and the circulating H3N2 wild-type may not be optimum, we ...
openaire   +2 more sources

Home - About - Disclaimer - Privacy